Durable clinical benefit following checkpoint blockade in patients with metastatic melanoma is associated with the presence of large T cell clones, defined as CD8 T cells expressing the same T cell receptor (TCR) and occupying more than 0.5% of the T cell repertoire in blood9,10. The gene discussed is CD8A; the disease is metastatic melanoma.